NEW YORK (GenomeWeb) – Horizon Discovery today announced it will acquire Vienna-based cell engineering firm Haplogen Genomics.

The purchase is for an initial consideration of £6.0 million ($9.1 million) in cash and the issue of new ordinary shares with further potential earn-out payments based on future performance. The purchase consists of gross cash consideration of £3.0 million and the issue of new ordinary shares having an aggregate value of £3.0 million. The deal includes the potential for payments of stock worth up to £3.9 million based on future performance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.